Expand SLDB Menu
SLDB MENU

SLDB Latest Press Releases

-- May 12, 2026 --

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 4:08 PM

-- May 7, 2026 --

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy Globe Newswire 8:00 AM

-- May 1, 2026 --

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- April 30, 2026 --

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy Globe Newswire 8:00 AM

-- April 28, 2026 --

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy Globe Newswire 8:00 AM

-- April 7, 2026 --

Solid Biosciences to Participate at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- March 19, 2026 --

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Globe Newswire 4:12 PM

-- March 11, 2026 --

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial Globe Newswire 1:01 PM

-- March 6, 2026 --

Solid Biosciences Announces Oversubscribed $240 Million Private Placement Globe Newswire 8:31 AM
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Globe Newswire 8:30 AM

-- March 2, 2026 --

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- February 9, 2026 --

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy Globe Newswire 8:00 AM

-- February 6, 2026 --

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Globe Newswire 8:00 AM

-- January 13, 2026 --

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 Globe Newswire 4:15 PM

-- January 12, 2026 --

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia Globe Newswire 4:15 PM
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia Globe Newswire 8:05 AM

-- January 6, 2026 --

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:00 AM

-- January 5, 2026 --

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:15 PM
Market Data Delayed 15 Minutes